SS-31 dosage chart

Reconstitution steps

1. 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
3. 3Gently swirl/roll until fully dissolved (clear solution).
4. 4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

Important Notes

Practical considerations for consistency, safety, and tolerability.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
• Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.
• Mild injection‑site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials; these typically resolve within hours.
• Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns.
• For doses requiring split injections (20 mg at this concentration), space injections at least 2 inches apart on different body regions.

How This Works

SS‑31 (elamipretide) is a cell‑permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure. By stabilizing cardiolipin‑protein interactions, SS‑31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues.

Preclinical research demonstrated that SS‑31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia‑reperfusion injury, neurodegeneration, chronic kidney disease, and age‑related muscle atrophy. In human clinical trials, SS‑31 showed favorable safety and tolerability profiles with no dose‑limiting toxicities. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six‑minute walk distance, leading to FDA accelerated approval in 2025.

Potential Benefits & Side Effects

Observations from preclinical models and human clinical trials.

• Stabilizes mitochondrial membranes and optimizes electron transport chain function.
• Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues.
• Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity).
• Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy.
• Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials.
• Injection‑site reactions (most common): Mild‑to‑moderate redness, itching, or transient discomfort at injection site; typically resolves within hours.
• Approximately 80% of patients in clinical trials experienced mild injection‑site reactions.
• No dose‑limiting toxicities or serious adverse events directly attributed to SS‑31 in published trials.
• Long‑term safety data beyond 12 weeks remains limited; extended use requires monitoring.

Lifestyle Factors

Complementary strategies to support mitochondrial health and optimize outcomes.

• Nutrition: Emphasize mitochondrial cofactors including B‑vitamins, CoQ10, magnesium, and alpha‑lipoic acid; maintain adequate protein intake to support muscle maintenance.
• Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.
• Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.
• Stress Management: Chronic stress increases oxidative burden; incorporate stress‑reduction practices such as meditation, breathwork, or yoga.
• Avoid Mitotoxins: Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.

Injection Technique

General subcutaneous injection guidance from clinical best‑practice resources.

• Site Preparation: Clean the vial stopper and injection site with alcohol swabs; allow to air‑dry completely (30–60 seconds) before proceeding.
• Drawing the Dose: Use a new sterile insulin syringe for each injection; draw the prescribed volume from the refrigerated vial; remove any visible air bubbles by gently tapping the syringe.
• Injection Angle: Pinch a fold of skin (approximately 1–2 inches); insert the needle at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean).
• Administration: Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds; wait 5–10 seconds before withdrawing the needle to minimize leakage.
• Site Rotation: Rotate systematically between injection sites (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent lipohypertrophy and local irritation.
• Post‑Injection: Apply gentle pressure with a clean alcohol swab or cotton ball for a few seconds; do not massage the site vigorously. A small bandage may be applied if needed.
• Disposal: Immediately place used syringes in a designated sharps container; never recap needles or dispose of them in regular trash.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. SS‑31 is currently FDA‑approved only for Barth syndrome under the brand name Forzinity; use for other conditions remains investigational. Always consult with qualified healthcare professionals before beginning any peptide protocol.

SS-31 dosage FAQs